Abstract Effects of intracerebroventircular (ICV), neuropeptide Y (NPY)(0.2–5.0 nmol) and its
C-terminal 13–36 amino acid (AA) fragment (0.4–2.0 nmol) have been examined with …

Evidence from animal studies has led to the proposal that neuropeptide Y (NPY) has
anxiolytic-like effects in rats after intracerebroventricular (icv) administration. The purpose of …

Nakajima, M., A. Inui, A. Asakawa, K. Momose, N. Ueno, A. Teranishi, S. Baba and M.
Kasuga. Neuropeptide Y produces anxiety via Y2-type receptors. Peptides 19 (2) 359–363 …

Evidence from animal and human studies suggests that neuropeptide Y (NPY) may be a
potent endogenous anxiolytic. The anatomic structures mediating this action of the peptide …

Human and animal studies suggest that neuropeptide Y (NPY), a peptide co-localized and
co-released with classical neurotransmitters, is involved in the pathogenesis of affective …

The receptor mechanisms mediating the neuropeptide Y (NPY)-induced suppression of
behavioural activity have been examined in the rat. The interaction of NPY with central …

Neuropeptide Y (NPY, 1 and 10 pmol), NPY Y1 receptor agonist [Leu31, Pro34] NPY (10
pmol) and Y2 agonist NPY13–36 (100 pmol) were administered unilaterally into the region …

Rats were given imipramine or zimeldine orally for three weeks and the brain levels of
neuropeptide Y-like immunoreactivity (NPY-LI) were measured. The concentration of NPY-LI …

This review aims to give a brief overview of NPY receptor distribution and physiology in the
brain and summarizes series of studies, test by test and region by region, aimed at …

Microinjection of neuropeptide V (NPY) into the nucleus tractus solitarius(NTS) induces an
initial and reversible fall in arterial pressure (AP) and heart rate (HA), along with a delayed …